Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
about
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenibVascular Complications of Cancer ChemotherapyBevacizumab for glioblastomaEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsReview of systemic therapies for locally advanced and metastatic rectal cancerNoninvasive imaging of cardiovascular injury related to the treatment of cancerAngiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysisThe Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial CellsManagement of CAD in Patients with Active Cancer: the Interventional Cardiologists' PerspectiveDrug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Treating venous thromboembolism in patients with cancer.Cancer and Venous Thromboembolic Disease: A Review.Ischemic Heart Disease: Special Considerations in Cardio-Oncology.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancerBevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategiesCancer therapy and cardiovascular risk: focus on bevacizumab.Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Management of antiangiogenic therapy-induced hypertension.NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyComparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumabCardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.Neurotoxicity of biologically targeted agents in pediatric cancer trialsBevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapyMechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential.Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy.Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study
P2860
Q21261282-B882FD63-1828-40FE-BA51-70A8D73AD581Q26766269-19DE65BE-8215-43AE-87ED-128E61FB7123Q26776307-B6ED166F-2C91-4019-A664-04C9FFACD09FQ26786618-F0517C96-6765-4A94-81E0-D0B8C78CFFC8Q27021105-139AD8CE-1C37-4864-9960-F0C46808A7C2Q27024715-4B30F7C7-A51F-462B-B820-1B3DCF9564E0Q28534015-41703A4B-433F-438A-BAC5-1D861A785C43Q28550616-6DE86171-8F3B-42A4-8F79-32C5588540F5Q29994512-9A6C9BFB-6187-4E1E-BD1E-3DA6143EDD76Q30616602-A4AC4190-B1F7-48D0-8F6A-980277B6DC22Q33400564-01088746-8E36-462A-A8E2-5E9DF5DA6DBFQ33439089-09DF004E-2696-4CAE-90F0-9EAFC4C4D68FQ33441165-D68CF4FE-7E21-4C43-8A0D-7B26BE2EACDBQ33564645-6A4F9616-51C0-406C-939D-3C2639564F64Q33683537-947AAB09-D95C-4ACA-93F9-7E82D52C49ABQ33904867-577C2073-AF2B-46DA-B435-DB534E01F02AQ34554380-A7378E96-B738-449D-AC89-848DCB7AE570Q34627103-A3F4B068-C508-4C05-B9A8-404658F6EEA4Q34637564-361A17B3-C98A-4866-A9B4-D55AE8DD705CQ35202464-95541A4C-C8A3-4FEE-802C-22997001114CQ35562745-0B22C931-AB49-4919-BEAE-75A2C1C19BD1Q35584182-0ABABE58-BD12-4CC8-804A-03AFF2B15BC6Q35703835-93A59D35-F7D5-441F-9F95-D6409625B7A5Q36008274-CE0D452C-31F1-48D1-969F-A9B4512355CAQ36170252-A52E3E61-FFF6-4B25-AD04-4203FF8B97AAQ36318627-B0CA2865-435E-4E9E-9EE9-11D948BFFD3EQ36473024-6FA95B97-0A36-47CC-883C-5D596CF831C0Q36751861-8CE213DF-F4C5-415C-8FB1-DCB0BA44510DQ36755620-46D0F8DE-0CCD-4126-89E4-E768ED8AE1A0Q36766221-D9EEBF83-182A-4BA1-90B5-16A7F4435A5CQ36862836-E1F6FA1A-389E-4180-BE82-FE67D407DC15Q36894689-4707393C-5869-4A7E-BF0F-759E76EB898DQ36942426-3CB9CB7A-92C0-4066-9397-49641535917BQ37038711-16901DA6-B524-4492-B274-0F28D01EFA47Q37042424-5D24FDC7-E770-4721-A39C-D29606F68555Q37052843-37F4EA10-3C30-4C87-9039-963EF0269E75Q37161885-ED9E3B3E-AB55-4D55-B4CC-32FBE2B4C425Q37390503-4641C3F0-C496-44CE-9B0C-0DEEF11CFFF9Q37696872-E4D567C1-3098-449C-93AE-5B684104BF16Q37719815-684FD8C2-D880-4770-AA84-7E735178DC9E
P2860
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk of cardiac ischemia and a ...... randomized controlled trials.
@en
Risk of cardiac ischemia and a ...... randomized controlled trials.
@nl
type
label
Risk of cardiac ischemia and a ...... randomized controlled trials.
@en
Risk of cardiac ischemia and a ...... randomized controlled trials.
@nl
prefLabel
Risk of cardiac ischemia and a ...... randomized controlled trials.
@en
Risk of cardiac ischemia and a ...... randomized controlled trials.
@nl
P2093
P2860
P921
P1433
P1476
Risk of cardiac ischemia and a ...... randomized controlled trials.
@en
P2093
Jeff Chuang
Sanjaykumar Hapani
Shenhong Wu
Vishal Ranpura
P2860
P304
P356
10.3109/02841860903524396
P577
2010-04-01T00:00:00Z